House Speaker John Boehner's willingness to agree to tax increases without a similar commitment from President Obama to cut spending helped push the Dow Jones Industrial Average up more than 100 points yesterday, snapping a three-day losing streak.
Yet the biggest loser on the day was Hewlett-Packard , which fell more than 3% after an analyst splashed cold water on speculation that its woeful performance would lead it to spin off its computer and printer division, saying it still needs the cash the division generates. The three following companies fell even harder than HP, some by even double-digit percentages.
First Majestic Silver
Now, don't go running over the cliff with them like a bunch of lemmings: It could just be a temporary situation. Let's first see whether they had good reason to fall, as panic-fueled routs can sometimes lead to excellent buying opportunities.
Clearly a lost cause
Shares of Clearwire sank below Sprint Nextel's buyout offer of $2.97 a share, as investors seemed reconciled to the fact they wouldn't be getting any more money out of the carrier -- or anyone else.
Minority shareholders contend that the original $2.90-a-share offer was too low, and the upgraded one wasn't any better. More like $5 a share would be reasonable, but other shareholders like Intel and Comcast representing 13% of outstanding shares have signed off on the deal.
Further pushing the deal in Sprint's direction was the agreement to provide $800 million in additional financing that would be exchangeable for Clearwire stock at $1.50 per share, serving to dilute minority interests further.
While it's not near what some investors wanted, the current price is 250% above the level it traded at in the middle of summer, so they've at least recovered some of their losses.
Hook, line, and sinker
Where Clearwire was falling because it wasn't getting enough money, shares of First Majestic Silver tumbled because it was paying too much. The silver miner agreed to buy Orko Silver for $2.72 Canadian, a 69% premium to its closing price on Friday.
First Majestic says it's getting a huge opportunity in the La Preciosa project, one of the world's largest undeveloped primary silver resources, particularly since its development timeline coincides with its own organic growth strategy. While the market wasn't buying it, the Fool's silver guru, Chris Barker, declares it's a "huge win" for shareholders on both sides of the trade. He thought Orko was a top stock for the year, and while it took almost the full year to pan out, particularly after Pan American Silver backed out of La Preciosa, it seems First Majestic saw the value inherent in the project.
Gambling with its future
Biotech Celsion has been turning up the heat on beating cancer by using heat-sensitive nanoparticles to deliver a hot "payload" of drug within tumors. Then when the heat's turned up with radio frequency ablation, the drugs are activated, and the tumor is killed from within. At least that's the theory it's trying to prove to the FDA, and results from its phase 3 HEAT trial are scheduled for next month. The company believes its proprietary liver cancer drug ThermoDox could be a $1 billion blockbuster opportunity and has already received authorization from European regulators to submit a marketing plan based on prior results. It's also been given orphan drug status here and abroad.
Not everyone is so enamored of the treatment, and TheStreet's Adam Feuerstein, known for sticking a pin in many a biotech balloon, says there are shorts who have intriguing arguments that Celsion will fail in its quest for progression-free survival study and suggests investors may want to sell their stock before that day arrives.
I noted previously there are many uses for thermal ablation such as Boston Scientific's hydrothermal ablation therapy to treat premenopausal women with menorrhagia, Covidien using it to treat liver lesions, and C.R. Bard treating a number of conditions with its equipment.
I still think Celsion looks promising, but let me know in the comments section whether you think it's still a good idea to get out early.
Ready for a resurrection
When it comes to dominating markets, it doesn't get much better than Intel's position in the PC microprocessor arena. However, that market is maturing, and Intel finds itself in a precarious situation longer term if it doesn't find new avenues for growth. In this premium research report on Intel, our analyst runs through all of the key topics investors should understand about the chip giant. Better yet, you'll continue to receive updates for an entire year. Click here now to learn more.
The article 3 Stocks the Dow Pushed Over the Cliff originally appeared on Fool.com.
Rich Duprey owns shares of Boston Scientific and Intel. The Motley Fool owns shares of Intel. Motley Fool newsletter services recommend Covidien and Intel. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.